A61K 40/36
Immune checkpoint inhibitors
A61K40/36 (Immune checkpoint inhibitors) appears on 90 US grants and 210 published applications in this corpus.
Search patents in A61K- Granted patents
- 90
- Published applications
- 210
- Assignees
- 106
- Inventors
- 423
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 3 |
| 2016 | 0 | 3 |
| 2017 | 0 | 9 |
| 2018 | 1 | 11 |
| 2019 | 6 | 20 |
| 2020 | 8 | 31 |
| 2021 | 10 | 25 |
| 2022 | 18 | 24 |
| 2023 | 6 | 29 |
| 2024 | 13 | 16 |
| 2025 | 18 | 18 |
| 2026 | 9 | 18 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Fusion constructs and methods of using thereof11 Aug 2026US 12,703,747 B2Precigen, Inc.
- Cell secreted minibodies and uses thereof16 Jun 2026US 12,655,226 B2Novartis AG
- Promoter having high activity in activated T-cell5 May 2026US 12,618,066 B2Shanghai Cell Therapy Group Co., Ltd.
- Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy28 Apr 2026US 12,612,598 B2Iovance Biotherapeutics, Inc.
- Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy3 Sep 2026US 2026/0258358 A1Board of Regents, The University of Texas System
- Processes for generating til products using pd-1/tigit talen double knockdown13 Aug 2026US 2026/0234556 A1Cellectis
- Immune rejection-resistant engineered cell16 Jul 2026US 2026/0201048 A1Nanjing Bioheng Biotech Co., Ltd.
- Transgenic recombinant immune cell specifically targeting tumor and use thereof16 Jul 2026US 2026/0201328 A1Shanghai Nk Celltech Co., Ltd.
- Methods and compositions for anti-cd45 based non-genotoxic conditioning14 May 2026US 2026/0130997 A1Beam Therapeutics Inc.
Most cited
By later US patents
- Mesenchymal stem cells as immunosuppressants110US 6,797,269 B2Osiris Therapeutics, Inc. · 2004
- CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell27US 10,253,086 B2Novartis AG · 2019
- Riluzole prodrugs and their use15US 10,485,791 B2Biohaven Therapeutics Ltd. · 2019
- Altering gene expression in modified T cells and uses thereof12US 11,203,758 B2The Trustees of the University of Pennsylvania · 2021
- Bispecific HER2 and CD3 binding molecules9US 10,519,248 B2Memorial Sloan Kettering Cancer Center · 2019